 NEW JERSEY, Dec. 07, 2020 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board. 